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osting by EAbstract Background: Over a period of years general anesthesia has been a standard anesthetic
technique for deﬁbrillation threshold (DFT) testing at the time of implant. DFT testing without
general anesthesia cover has gained limited acceptance. Use of local anesthesia combined with deep
sedation for DFT testing might facilitate and simplify these procedures by reducing the procedural
time, staff time, avoiding inefﬁcient service in organizing anesthetic cover; thereby improving
patient compliance.
Objective: The objective of this study was to evaluate feasibility, safety and efﬁcacy of conscious
sedation for DFT testing during Implantable cardioverter deﬁbrillators (ICD) implantation.
Method: Data of 87 non-selected patients who achieved adequate sedation with titrated doses of
midazolam and pethidine were analyzed retrospectively. These medications were administered by
a circulating nurse under the supervision of the implanting physicians. All hemodynamic measures,
treatment and complications were monitored and recorded throughout the procedure.
Results: A retrospective analysis of data from 87 patients who underwent ICD implantation and
DFT testing under conscious sedation at our center was reported. The mean dose of midazolam
and pethidine administered was 4.9 ± 1.8 and 47.7 ± 20 mg, respectively. During the period of con-
scious sedation, no patient depicted episode of sustained apnea. No major complication or mortality
was reported.14777714x8765; fax: +966
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210 A. Al Fagih et al.Conclusion: Use of conscious sedation as an alternative to the use of general anesthesia for DFT test-
ing during ICD implantation is found to be feasible, safe and effective, with an added advantage of
reduced procedural time and improved patient compliance.
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Implantable cardioverter deﬁbrillators (ICDs) were ﬁrst intro-
duced in early 1980s (Curtis, 2008). ICDs offer a signiﬁcant
opportunity to decrease procedural morbidity and medical
costs in the care of patients with life-threatening ventricular
arrhythmias (who otherwise would have required a sternotomy
or thoracotomy for device insertion) (Bardy et al., 1993). To en-
sure that the system has an acceptable deﬁbrillation threshold
safety margin at the time of implant, the standard of care that
has long been accepted is the deﬁbrillation threshold (DFT)
testing (Mainigi and Callansm, 2006). DFT testing has tradi-
tionally been performed under general anesthesia. Despite the
widespread use of general anesthesia for this procedure, orga-
nizing anesthetic cover for the procedure can sometimes be a
challenging experience for the cardiologist. In addition, pa-
tients with poor LVEF are prone to cardiovascular complica-
tion under general anesthesia (Singh et al., 2004).
The list of challenges using GA include procedural delay,
cardiovascular complications during treatment, patient appre-
hension and incompatibility, waste of staff time and an inefﬁ-
cient service (Foster, 1995; Eastman et al., 1995). Direct
hemodynamic and electrophysiological effects of general anes-
thetics on heart and on deﬁbrillation energy requirement have
been reported. Animal studies have shown an increase in deﬁ-
brillation energy requirement in the presence of vasopressor
(Knight et al., 1999). To overcome these challenges, newer
techniques have been developed.
Physicians in a variety of specialties have experience in pro-
viding safe sedation for unpleasant procedures. In cardiology,
wide spread use of transesophageal echocardiography has led
to familiarity with administration of sedative agents (Working
PartyReport, 1993; Saltissi et al., 1994).Moreover, an increased
cost anddifﬁculties inarranginganesthetic coverhave inﬂuenced
the cardiologist’s inclination towards the use of sedative agents.
It is now possible to place the ICDs under local anesthesia
in electrophysiology laboratories with techniques similar to
those used for the insertion of permanent pacemakers. Despite
the fact that this technique has a similar safety and reliability
proﬁle, and the cardiorespiratory functions remain uncompro-
mised, DFT during implantation of ICD without general anes-
thesia has gained limited acceptance (Singh et al., 2004; Tung
and Bajaj, 1995). In order to identify the successful applicabil-
ity of the alternative techniques for DFT testing at the time of
implantation of ICD in the absence of general anesthesia, this
study was conducted with the objective of evaluating the feasi-
bility, safety and efﬁcacy of conscious sedation for DFT test-
ing during ICD implantation (without anesthesia cover).
2. Method
2.1. Data collection
Data from 250 patients who underwent ICD implantation and
deﬁbrillation threshold testing under conscious sedation at ourcenter between March 2008 and November 2009 were com-
piled. Data from 130 patients were randomly selected for anal-
ysis. Forty three patients were excluded from analysis due to
insufﬁcient data. Written informed consent was obtained from
all the patients. All the baseline characteristics of the patients
were thoroughly reviewed.
2.2. Data extraction and assessment parameters
Data relating to patient characteristics, procedure, and safety
and efﬁcacy outcomes were analyzed and the results were
interpreted.
2.2.1. Patient characteristics
Demographic characteristics of the patients pertaining to age,
gender, height and weight were recorded. BMI was calculated
from the available information to assess obesity. Primary
underlying cardiac conditions such as coronary artery disease,
dilated cardiomyopathy, hypertrophic cardiomyopathy, con-
genital abnormalities and valvular involvement were looked
for. A thorough medical history including history of congestive
heart failure, hypertension, diabetes mellitus, clinical ventricu-
lar arrhythmia and chronic obstructive pulmonary disease was
recorded. History of medications such as digoxin, beta-block-
ers, calcium channel blockers and angiotensine converting en-
zyme inhibitor (ACEI) or angiotensine receptor blockers
(ARBs) was also incorporated. Creatinine values were re-
corded and classiﬁed as normal and abnormal. Quantitative
left ventricular ejection fraction for each patient was recorded.
2.2.2. Procedure
The implantation procedure was conducted in a clean and ster-
ilized procedure room equipped for emergency intubation and
ventilation. All procedures were devoid of anesthetic cover. Sed-
ative drugs namely midazolam and pethidine were ordered by
the implantation physician and administered by the circulating
nurses in titrated doses as needed to achieve adequate sedation.
The effectiveness of sedationwas closelymonitoredbyobserving
the patient’s state of consciousness, response to interrogation or
other stimuli, respiration pattern, eyelash reﬂex, oxygen satura-
tion, blood pressure and cardiac rhythm. Continuous pulse oxy-
metry and cyclic non-invasive blood pressure were monitored
throughout the procedure. Anexate (ﬂumazenil) availability
was mandatory in the procedure room as an antidote for midaz-
olam adverse effect. Deﬁbrillation threshold testing was per-
formed once in each patient unless the ﬁrst attempt failed.
The procedural time was recorded. Dose of midazolam and
pethidine administered to the patients was tabulated.
2.2.3. Safety and efﬁcacy assessment
Side effects such as hypotension, hypoxia and apnea were re-
corded. Supportive measures adapted such as inotropic agents,
oxygen supplementation, antidote requirement and intubation
were recorded. Complications like bleeding requiring transfu-
sion, major vessel tear or perforation, pericardial effusion or
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tamponade, infection of the new device within the ﬁrst 30 days,
hematoma requiring drainage, ventricular arrhythmia requir-
ing DC shock, and other technical complications were as-
sessed. Mortality was also recorded.
3. Results
3.1. Patient characteristics
Data of 87 patients were analyzed retrospectively. The mean
age was 54.66 year (range: 17–76). Eighty two percent of the
subjects was male. The mean height and weight were
167.74 cm and 75.23 kg, respectively. Forty three percent of
study population was overweight. Majority of the patients
(70%) were diagnosed to have coronary artery disease. Dilated
cardiomyopathy and valvular diseases were accounted for less
than 25%. Around 6% of patients had no reported structural
heart disease. The mean quantitative left ventricular ejection
fraction was 25.8% (range: 10–60). The medical history of
the patients depicted congestive heart failure (CHF) (63%),
hypertension (32%), diabetes mellitus (26%), clinical ventricu-Table 1 Patient characteristics.
Characteristics Frequency [Mean(range)/N(%)]
Number of patients 87
Demographic data
Age 54.66 years (17–76 years)
Gender
Male 71 (82%)
Female 16 (18%)
Height 167.74 cm (151–188 cm)
Weight 75.23 kg (51–110 kg)
BMI 26.79 (18.11–42.44)
Under weight 2 (2%)
Normal 30 (35%)
Over weight 37 (43%)
Obese 18 (20%)
Primary underlying cardiac
disease
82 (94%)
Coronary artery disease 60 (70%)
Dilated cardiomyopathy 18 (20%)
Valvular diseases 4 (4%)
None 5 (6%)
LVEF 25.80% (10–60%)
Medical history
Congestive heart failure 55 (63%)
Hypertension 28 (32%)
Diabetes mellitus 23 (26%)
Clinical ventricular arrhythmia 2 (2%)
Chronic obstructive pulmonary
disease
7 (8%)
Medications
Digoxin 24 (27%)
Beta-blockers 66 (76%)
Calcium channel blockers 5 (6%)
ACEI/ARBs 76 (87%)
Abnormal creatinine values 35 (40%)
ACEI, angiotensin converting enzyme inhibitor; ARBs, angiotensin
receptor blockers; LVEF, left ventricular ejection fraction.lar arrhythmia (CVA) (2%) and chronic obstructive pulmon-
ary disease (COPD) (8%). A greater proportion of the
subjects received ACEI/ARBs (87%) and beta-blockers
(76%); while a relatively small proportion received digoxin
(27%) and calcium channel blockers (6%). Abnormal creati-
nine values were recorded in 40% of the subjects Table 1.
3.2. Conscious sedation execution
The procedure was conducted once in each subject. The mean
procedural time was 52 min (range: 30–110 min). The mean
concentration of midazolam and pethidine administered was
4.9 ± 1.8 and 47.7 ± 20.0 mg, respectively Table 2. The most
frequently used dose of midazolam was 4 mg accounted for
(29%) and 50 mg of pethidine (53%).
3.3. Safety and efﬁcacy outcomes
Adequate sedation was achieved in all the subjects. No major
complications or mortalities were observed. Though side
effects such as hypotension and hypoxia were recorded in 5Table 2 Conscious sedation induction.
Frequency (%)
Procedural time in minutes
30–50 45 (52)
51–70 38 (44)
71–90 2 (2)
91–110 2 (2)
Midazolam dose in mg
2 11 (13)
3 6 (7)
4 25 (29)
5 14 (16)
6 14 (16)
7 4 (4)
8 13 (15)
Pethidine dose in mg
25 27 (31)
50 46 (53)
75 9 (10)
100 5 (6)
Table 3 Safety and efﬁcacy outcomes.
Outcome Frequency (%)
Sedation achieved 87 (100)
Side eﬀects
Hypoxia 3 (3)
Hypotension 5 (6)
Apnea 0 (0)
Supportive measures
Inotropic support 4 (5)
Oxygen supplementation 3 (3)
Antidote 1 (1)
Intubation 0 (0)
Major complications 0 (0)
Death 0 (0)
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ported. 7 out of 8 side effects were observed in patient group
receiving 50 mg pethidine. Inotropic support, oxygen supple-
mentation and antidote were required in 4 (5%), 3 (3%),
and 1 (1%) subjects, respectively. No patient required intuba-
tion Table 3.4. Discussion
The developments of reliable trans-venous leads systems and
down-sized generators have greatly facilitated the placement
of ICDs (Natale et al., 1996). However, optimal anesthetic
and surgical techniques for the implantation of these devices
remain controversial (Foster, 1995; Eastman et al., 1995).
Review of the recent published reports reveals that the
majority of electrophysiologists continue to place ICDs in
operating rooms under general anesthesia (Wever et al.,
1995; Zipes and Roberts, 1995; Villacastı´n et al., 1996). Argu-
ing that intravenous sedation fails to ensure adequate ventila-
tion in critically ill patients and that ventilator difﬁculties may
contribute to hemodynamic deterioration, Epstein and Kay
(1994) advocated routine elective endotracheal intubation
and mechanical ventilation for the placement of ICDs.
Whether the general anesthesia or conscious sedation inﬂu-
ences the deﬁbrillation threshold remains a matter of debate.
Moerman et al. (1998) have shown that both types of anesthe-
sia (local or general) did not inﬂuence the threshold of
cardioversion.
Physicians in a variety of specialties have experienced in
providing safe sedation for unpleasant procedures. In cardiol-
ogy the wide spread use of transesophageal echocardiography
has led to familiarity with administration of sedative agents
(Saltissi et al., 1994). Moreover, an increased cost and difﬁcul-
ties in arranging anesthetic cover have inﬂuenced the cardiolo-
gist’s inclination towards the use of sedative agents.
Many sedative agents have been shown to be safe and effec-
tive for achieving their purpose with minimal limitation. The
choices are however open for the physicians depending up
on their experience and comfort. Canessa et al. (1991) com-
pared thiopental, propofol, etomidate and midazolam and
found midazolam to be longer acting. Midazolam is used as
a sedative agent in our study considering this characteristic
as one of its advantages over other agents. Thiopental and pro-
pofol were associated with hypotension and etomidate was
associated with pain on injection on myoclonus (Canessa
et al., 1991). Gale et al. (1993) found that the time of awaken-
ing with midazolam was triple of that with propofol and
methohexital. Goldner et al. (1998) also suggested the use of
morphin and midazolam in their study. In one report, propofol
resulted in hypotension and signiﬁcant decrease in heart rate
and apnea which required mechanical ventilation, but it has
been shown to be good alternative to general anesthesia for
ICD implantation (Kick et al., 1996; Hara et al., 1999). On
the contrary, our analysis reported that no patient developed
apnea when they were sedated with the titrated dose of midaz-
olam and pethidine. Raipancholia et al. (2001) used pethidine
to augment sedation by midazolam in which the requirement
of pethidine varied inversely with age, with no patients requir-
ing intubation or hospital admission. Similar observation was
noted in our study, wherein no patient required assisted venti-
lation by face mask or endotracheal intubation. However, 7out of 8 of the side effects observed in our study were observed
in patients administered with 50 mg pethidine.
Recall of shocks has not been addressed widely in previous
studies. In one study including 149 patients who underwent
external cardioversion, only ﬁve patients found it very unpleas-
ant, but all patients had total amnesia with regards to the pro-
cedure with midazolam sedation (Dellinger et al., 1988).
Valtonen et al. reported the experience of 5 patients sedated
twice with propofol and thiopentone for cardioversion. They
assessed the anesthesia procedure with propofol as being more
pleasant (Valtonen et al., 1988) similarly, in our study; all pa-
tients were unable to recall the deﬁbrillation testing.
One of the limitations of the current study is the cost which
was not targeted, but few reports have clearly shown signiﬁ-
cant reduction in cost when a cardiologist administer sedation
without anesthesia cover (Botkin et al., 2003). However, the
technique did not require an anesthetist as the agents were
administered by circulating nurses under the supervision of
the implanting physician, hence the direct cost to staff reduced.
5. Conclusion
Use of conscious sedation (intravenous midazolam and pethi-
dine) for DFT testing during ICD implantation is a safe and
effective alternative to general anesthetics in a well-equipped
electrophysiology laboratory in the hands of well-trained
health care personnel and experienced cardiologist.
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